0.03
-2.86%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Immuron
Its shares trade on ASX under the ticker IMC.AX. It has been listed since 30 April 1999. In the fiscal year to 30 June 2026, it reported revenue of A$7.7m and a net loss of A$3.8m. At that date it held total assets of A$13.0m and shareholders' equity of A$11.0m.
Immuron Ltd. engages in the research and development of oral immunotherapy, and product sales which focuses on bovine-colostrum with antibodies of choice for the treatment and prevention of a range of infectious and immune modulated diseases. The company is headquartered in Melbourne, Victoria. The firm focuses on the research and development of bovine-colostrum enriched with antibodies of choice for the treatment and prevention of a range of infections and immune modulated diseases. The firm has three segments: Research and Development (R&D), HyperImmune Products and Corporate. The R&D segment focuses on the Company's research and development projects performed in Australia and Israel. The firm sells and licenses its product, Travelan. The HyperImmune Products segment is engaged in its Travelan product's activities, which occur in Australia, New Zealand and Canada. The Corporate segment's activities primarily occur in Australia. The company also develops products for applications, including non-alcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH) and clostridium difficile (C-Diff), diabetes, colitis and uropathogenic escherichia coli (UPEC). The firm also offers Protectyn, IMM 124-E-NASH and IMM 529-CDI.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 30 Apr 1999
- Employees
- 25
- Website
- immuron.com.au ↗
Leadership
Pay as last reported
- Mr. Paul BrennanNon-Executive Independent Chairman of the BoardA$22,459
- Mr. Steven LydeamoreChief Executive OfficerA$32,784
- Mr. Phillip HainsChief Financial Officer, Company Secretary
- Dr. Jerry KanellosChief Operating OfficerA$392,726
- Dr. Jeannette JoughinNon-Executive Director
- Mr. Daniel PollockNon-Executive Independent DirectorA$94,875
- Prof. Ravi SavarirayanNon-Executive Independent DirectorA$65,001
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Immuron Ltd has several strengths that give it a competitive advantage in the market. Firstly, the company has a strong and experienced management team with a track record of success in the biotech industry. This provides a solid foundation for decision-making and strategy execution.
- Additionally, Immuron Ltd has developed a unique platform technology that allows for the creation of novel and effective therapeutic products. This technology has the potential to revolutionize the treatment of certain diseases and provides the company with a distinct market edge.
- The company also benefits from a diverse product portfolio, with multiple candidates in various stages of development. This diversity mitigates the risk associated with relying solely on one product and provides multiple revenue streams for the company.
Weaknesses
- Despite its strengths, Immuron Ltd also faces certain weaknesses that need to be addressed. One key weakness is the company's limited financial resources. This constraint may hinder the company's ability to fully exploit its technology and commercialize its products.
- Another weakness lies in the company's heavy dependence on its research and development pipeline. Delays or failures in the pipeline could significantly impact Immuron Ltd's revenue generation and overall growth prospects.
Opportunities
- Immuron Ltd operates in an industry with immense growth potential. The rising prevalence of various diseases, coupled with increasing healthcare expenditure, presents significant opportunities for the company to expand its market reach and capture a larger share.
- Furthermore, advancements in technology and the growing trend towards personalized medicine open doors for Immuron Ltd to develop targeted therapies tailored to individual patients, which can enhance treatment efficacy and drive demand for its products.
Threats
- Immuron Ltd operates in a highly competitive landscape, with numerous biotech companies vying for market share. This intensifying competition poses a threat to the company's market position and profitability.
- Additionally, regulatory uncertainty and stringent approval processes for new drugs and treatments can pose significant challenges for Immuron Ltd's product development and commercialization efforts.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.